We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Discontinues Crohn’s Candidate; Returns Rights to ChemoCentryx
GSK Discontinues Crohn’s Candidate; Returns Rights to ChemoCentryx
September 30, 2013
GlaxoSmithKline has decided to end further study of its Crohn’s disease drug candidate vercirnon following poor pivotal trial results, returning all rights to the drug to ChemoCentryx.